Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Other Accumulated Expenses: 2019-2025

Historic Other Accumulated Expenses for Legend Biotech (LEGN) over the last 5 years, with Sep 2025 value amounting to $147.2 million.

  • Legend Biotech's Other Accumulated Expenses fell 10.72% to $147.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.2 million, marking a year-over-year decrease of 10.72%. This contributed to the annual value of $166.2 million for FY2024, which is 35.87% up from last year.
  • Latest data reveals that Legend Biotech reported Other Accumulated Expenses of $147.2 million as of Q3 2025, which was up 6.01% from $138.8 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Other Accumulated Expenses registered a high of $184.1 million during Q4 2022, and its lowest value of $80,096 during Q1 2021.
  • Over the past 3 years, Legend Biotech's median Other Accumulated Expenses value was $146.4 million (recorded in 2023), while the average stood at $147.1 million.
  • In the last 5 years, Legend Biotech's Other Accumulated Expenses skyrocketed by 180,579.81% in 2021 and then crashed by 33.57% in 2023.
  • Quarterly analysis of 5 years shows Legend Biotech's Other Accumulated Expenses stood at $123.6 million in 2021, then soared by 49.01% to $184.1 million in 2022, then plummeted by 33.57% to $122.3 million in 2023, then surged by 35.87% to $166.2 million in 2024, then dropped by 10.72% to $147.2 million in 2025.
  • Its last three reported values are $147.2 million in Q3 2025, $138.8 million for Q2 2025, and $116.8 million during Q1 2025.